141,893 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by EAM Investors LLC

EAM Investors LLC bought a new stake in NovoCure Limited (NASDAQ:NVCR) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 141,893 shares of the medical equipment provider’s stock, valued at approximately $4,228,000.

Other institutional investors also recently made changes to their positions in the company. Lindbrook Capital LLC boosted its position in NovoCure by 189.2% during the 4th quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 1,213 shares during the period. Blue Trust Inc. boosted its holdings in shares of NovoCure by 70.7% during the fourth quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 781 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of NovoCure during the fourth quarter worth about $70,000. Versant Capital Management Inc lifted its position in NovoCure by 35.8% in the 4th quarter. Versant Capital Management Inc now owns 3,341 shares of the medical equipment provider’s stock valued at $100,000 after purchasing an additional 880 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in NovoCure by 57.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider’s stock valued at $129,000 after purchasing an additional 1,575 shares during the period. 84.61% of the stock is owned by institutional investors.

NovoCure Trading Down 0.5 %

Shares of NASDAQ:NVCR opened at $16.46 on Wednesday. The firm has a fifty day moving average of $19.31 and a two-hundred day moving average of $21.57. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. NovoCure Limited has a 12-month low of $11.70 and a 12-month high of $34.13. The firm has a market capitalization of $1.81 billion, a P/E ratio of -11.76 and a beta of 0.65.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.27). NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The firm had revenue of $161.27 million for the quarter, compared to analyst estimates of $161.30 million. On average, equities analysts expect that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NVCR. JPMorgan Chase & Co. reduced their price objective on NovoCure from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Wedbush reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of NovoCure in a report on Monday, January 13th. StockNews.com cut shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of NovoCure in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, NovoCure presently has an average rating of “Hold” and an average price target of $34.50.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.